|
|
Volumn 8, Issue 10, 2009, Pages 757-758
|
|
Late-stage osteoporosis drugs illustrate challenges in the field
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALENDRONIC ACID;
AMG 785;
BISPHOSPHONIC ACID DERIVATIVE;
CDP 7851;
DENOSUMAB;
MONOCLONAL ANTIBODY;
ODANACATIB;
PARATHYROID HORMONE[1-34];
SCLEROSTIN;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
UNCLASSIFIED DRUG;
ZOLEDRONIC ACID;
ARTICLE;
CLINICAL TRIAL;
DISEASE COURSE;
DIZZINESS;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MECHANISM;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL SYMPTOM;
GOLD STANDARD;
HEALTH CARE AVAILABILITY;
HUMAN;
LEG CRAMP;
NAUSEA;
OSSIFICATION;
OSTEOLYSIS;
OSTEOPOROSIS;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
RISK REDUCTION;
ANTIBODIES, MONOCLONAL;
BONE DENSITY;
BONE DENSITY CONSERVATION AGENTS;
DRUG DELIVERY SYSTEMS;
HUMANS;
OSTEOPOROSIS;
RANK LIGAND;
TIME FACTORS;
|
|
EID: 70349635127
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3015 Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|